Director of Delhi's AIIMS Dr Randeep Guleria has told Aajtak that Covaxin's data for children after completion of the Phase 2/3 trials will be available by September and the approval is expected the same month. Dr Guleria also said that if Pfizer and BioNTech's vaccine gets a green signal in India then that could be an option for children too. Watch the video.